Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.74 |
| ▸ | CA2 | P00918 | 6/20 | 0.74 |
| ▸ | EEF2K | O00418 | 2/20 | 0.64 |
| ▸ | EEF2 | P13639 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | PLK4 | O00444 | 1/20 | 0.64 |
| ▸ | JAK2 | O60674 | 1/20 | 0.64 |
| ▸ | EGFR | P00533 | 1/20 | 0.64 |
| ▸ | TYK2 | P29597 | 1/20 | 0.64 |
| ▸ | FLT3 | P36888 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | ITK | Q08881 | 1/20 | 0.64 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.64 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10325952 | 0.98 | CA1 (0.77) | CA1CA2EEF2KEEF2MEN1 | |
| Water SCHEMBL11782764 | 0.98 | CA1 (0.72) | CA1CA2EEF2KEEF2MEN1 | |
| Bromide SCHEMBL1044433 | 0.98 | CA1 (0.72) | CA1CA2EEF2KEEF2MEN1 | |
| Hydrochloric Acid SCHEMBL1877207 | 0.98 | CA1 (0.77) | CA1CA2EEF2KEEF2MEN1 | |
| SCHEMBL10325611 | 0.94 | CA1 (0.71) | CA1CA2EEF2KEEF2MEN1 | |
| SCHEMBL1044084 | 0.94 | CA1 (0.71) | CA1CA2EEF2KEEF2MEN1 | |
| SCHEMBL1044087 | 0.94 | CA1 (0.71) | CA1CA2EEF2KEEF2MEN1 | |
| Hydrochloric Acid SCHEMBL1179416 | 0.92 | CA1 (0.74) | CA1CA2EEF2KEEF2MEN1 | |
| Hydrochloric Acid SCHEMBL1179414 | 0.92 | CA1 (0.74) | CA1CA2EEF2KEEF2MEN1 | |
| SCHEMBL3457638 | 0.88 | EEF2K (0.70) | CA1CA2EEF2KEEF2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9072729-B2 | Method for treating fibrosis and cancer with imidazolium and imidazolinium compounds | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-07-07 | — | — | US | claimed |
| US-20110178040-A1 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2011-07-21 | — | — | US | claimed |
| US-20110028513-A1 | METHOD FOR TREATING NEUROLOGICAL DISORDERS WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2011-02-03 | — | — | US | claimed |
| EP-2271338-A1 | METHOD FOR TREATING NEUROLOGICAL DISORDERS WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | Agency for Science, Technology And Research (SG) | 2011-01-12 | — | — | EP | claimed |
| EP-2249832-A1 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | Agency for Science, Technology And Research (SG) | 2010-11-17 | — | — | EP | claimed |
| WO-2009123569-A1 | METHOD FOR TREATING NEUROLOGICAL DISORDERS WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2009-10-08 | — | — | WO | claimed |
| WO-2009096905-A1 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2009-08-06 | — | — | WO | claimed |
| US-20160331727-A9 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-11-17 | — | — | US | disclosed |
| US-20160000757-A1 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-01-07 | — | — | US | disclosed |
| US-9072729-B2 | Method for treating fibrosis and cancer with imidazolium and imidazolinium compounds | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-07-07 | — | — | US | disclosed |
| EP-2803356-A1 | Method for treating neurological disorders with imidazolium and imidazolinium compounds | Agency for Science, Technology and Research (SG) | 2014-11-19 | — | — | EP | disclosed |
| US-20110178040-A1 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2011-07-21 | — | — | US | disclosed |
| US-20110178040-A1 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2011-07-21 | — | — | US | disclosed |
| US-20090110832-A1 | PLANOGRAPHIC PRINTING PLATE MATERIAL, PLANOGRAPHIC PRINTING PLATE, PLANOGRAPHIC PRINTING PLATE PREPARING PROCESS AND PRINTING PROCESS EMPLOYING PLANOGRAPHIC PRINTING PLATE | KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) | 2009-04-30 | — | — | US | disclosed |
| US-20080138701-A1 | BATTERY-INTEGRATED SEMICONDUCTOR MODULE AND METHOD FOR PRODUCING THE SAME | KABUSHIKI KAISHA TOSHIBA (JP) | 2008-06-12 | — | — | US | disclosed |
| EP-0695316-A1 | URETHANE MODIFIED EPOXY RESIN COMPOSITIONS | Ciba SC Holding AG (CH) | 1996-02-07 | — | — | EP | disclosed |
| WO-1995021879-A1 | URETHANE MODIFIED EPOXY RESIN COMPOSITIONS | CIBA-GEIGY AG (CH) | 1995-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028513-A1 | METHOD FOR TREATING NEUROLOGICAL DISORDERS WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | SMN1; SMN2, INA, NLN | CA1 142/4885CA2 784/4885EEF2K 1187/4885 |
| US-20110178040-A1 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | MMP1, MYLK, MMP8 | CA1 3739/4885CA2 1777/4885EEF2K 1268/4885 |
| US-20160331727-A9 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | MMP1, MYLK, MMP8 | CA1 3739/4885CA2 1777/4885EEF2K 1268/4885 |
| US-20160000757-A1 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | MMP1, MYLK, MMP8 | CA1 3739/4885CA2 1777/4885EEF2K 1268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.